Posted by Michael Wonder on 18 Feb 2026
PHARMAC proposes funding new treatments that could transform early care for people with chronic lymphocytic leukaemia, a type of blood cancer
18 February 2026 - People in New Zealand living with chronic lymphocytic leukaemia could soon benefit from funded access to targeted treatments under a new proposal from PHARMAC.
PHARMAC is consulting on a change that would fund two new treatment combinations - venetoclax with ibrutinib, and venetoclax with obinutuzumab - for people with chronic lymphocytic leukaemia. If approved, funding would begin on 1 May 2026.
